Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
Grifols to acquire Pharmalink's Xepol programme for post-polio syndrome
- Login or register to post comments
- Feed: Pediatrics News Feed
- Original article